|
|
|
|
|
|
|
19/09/2007 |
|
|
Effect of miglustat on bone disease in adult Type 1 Gaucher Disease (GD1) |
|
|
|
|
 |
|
|
|
|
|
|
|
LONDON – 17 September 2007 – Actelion UK Ltd announces the publication of "Effect of miglustat on bone disease in adult type 1 Gaucher disease: a pooled analysis of three multinational open label studies" (Pastores et al.) in Clinical Therapeutics, vol 29, number 8, 2007.
|
|
 |
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
|
|
|
|
|
|
|
30/09/2007 |
|
|
One-Year results on the use of miglustat (Zavesca®) in Niemann-Pick type C disease |
|
|
|
|
|
|
|
|
|
|
|
|
ALLSCHWIL, SWITZERLAND – 30 August 2007 – Actelion Ltd (SWX: ATLN) announced today the online publication in “The Lancet Neurology “ of the one-year results from a randomized controlled study evaluating safety and efficacy of miglustat (Zavesca®) in patients suffering from Niemann-Pick type C (NP-C) [1]. NP-C is an autosomal recessive genetic disease affecting children, juveniles and adults, characterized by progressive, severe and heterogeneous neurological manifestations, and reduced life expectancy [2]. Zavesca® is not currently licensed for the treatment of NP-C. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06/06/07 |
|
|
Santé Communications Joins FD |
|
|
|
|
|
|
|
|
|
|
|
|
Santé Communications Ltd is delighted to announce that, from today, it becomes part of the FD (Financial Dynamics) group. As most of you will know, we have been expanding our global offering for a number of years and the FD network will greatly enhance our ability to do this on behalf of our clients. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17/04/07 |
|
|
EVERY CLICK COUNTS for Sport |
|
|
|
|
|
|
|
|
|
|
|
|
17th April 2007, World Haemophilia Day – A new web resource for people with haemophilia, their carers and healthcare professionals was launched today with an innovative fund-raising campaign that aims to get more UK youngsters with haemophilia involved in sports. |
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01/02/07 |
|
|
Medical Editor of Daily Telegraph to Join Santé |
|
|
|
|
|
|
|
|
|
|
|
|
Santé Communications are delighted to announce that one of the UK’s most respected medical journalists is set to join the Agency.
National newspaper medical journalist, Celia Hall is leaving The Daily Telegraph for a new career with Santé Communications, a specialist healthcare communications consultancy, where she becomes Director of Media Strategy, a newly created post, as the agency seeks to expand its media offering.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29/01/07 |
|
|
Baxter's Advate Receives Room Temperature Storage Approval |
|
|
|
|
|
|
|
|
|
|
|
|
Compton, England, 29th January 2007 – Baxter Healthcare Ltd. today announced the approval of room temperature storage for Advate, the only factor VIII product processed without blood-based additives. The approval in the European Union allows for 2 months of room temperature storage within the approved shelf life of 24 months at 2° to 8°C. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
